BR112021020027A2 - Compostos, composições e métodos - Google Patents

Compostos, composições e métodos

Info

Publication number
BR112021020027A2
BR112021020027A2 BR112021020027A BR112021020027A BR112021020027A2 BR 112021020027 A2 BR112021020027 A2 BR 112021020027A2 BR 112021020027 A BR112021020027 A BR 112021020027A BR 112021020027 A BR112021020027 A BR 112021020027A BR 112021020027 A2 BR112021020027 A2 BR 112021020027A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
compounds
tautomer
stereoisomer
Prior art date
Application number
BR112021020027A
Other languages
English (en)
Inventor
A Estrada Anthony
De Vicente Fidalgo Javier
A Feng Jianwen
K Sweeney Zachary
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of BR112021020027A2 publication Critical patent/BR112021020027A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

compostos, composições e métodos. a presente invenção refere-se genericamente a inibidores de lrrk2, ou um sal farmaceuticamente aceitável, análogo isotopicamente enriquecido, tautômero, estereoisômero, mistura de estereoisômeros, profármaco, ou composição farmacêutica dos mesmos, e métodos de preparação e seu uso.
BR112021020027A 2019-04-11 2020-04-10 Compostos, composições e métodos BR112021020027A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832775P 2019-04-11 2019-04-11
PCT/US2020/027742 WO2020210684A1 (en) 2019-04-11 2020-04-10 Compounds, compositions and methods

Publications (1)

Publication Number Publication Date
BR112021020027A2 true BR112021020027A2 (pt) 2021-12-07

Family

ID=72752101

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020027A BR112021020027A2 (pt) 2019-04-11 2020-04-10 Compostos, composições e métodos

Country Status (16)

Country Link
US (1) US20220220094A1 (pt)
EP (1) EP3953348A4 (pt)
JP (1) JP2022526015A (pt)
KR (1) KR20210151887A (pt)
CN (1) CN113939294A (pt)
AR (1) AR118641A1 (pt)
AU (1) AU2020272045A1 (pt)
BR (1) BR112021020027A2 (pt)
CA (1) CA3136447A1 (pt)
EA (1) EA202192530A1 (pt)
IL (1) IL287120A (pt)
MA (1) MA55624A (pt)
MX (1) MX2021012392A (pt)
SG (1) SG11202111058XA (pt)
WO (1) WO2020210684A1 (pt)
ZA (1) ZA202107499B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL275480B2 (en) 2017-12-20 2023-10-01 Denali Therapeutics Inc A process for the preparation of pyrimidinyl-4-aminopyrazole compounds
CN116120291B (zh) * 2023-04-11 2023-06-30 英矽智能科技(上海)有限公司 吲唑类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2638031T3 (pt) * 2010-11-10 2018-03-10
KR102553188B1 (ko) * 2016-06-16 2023-07-11 데날리 테라퓨틱스 인크. 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서 피리미딘-2-일아미노-1h-피라졸
US20200157081A1 (en) * 2017-05-24 2020-05-21 Denali Therapeutics Inc. Compounds, compositions and methods
IL275480B2 (en) * 2017-12-20 2023-10-01 Denali Therapeutics Inc A process for the preparation of pyrimidinyl-4-aminopyrazole compounds

Also Published As

Publication number Publication date
EP3953348A4 (en) 2023-01-18
EP3953348A1 (en) 2022-02-16
SG11202111058XA (en) 2021-11-29
CA3136447A1 (en) 2020-10-15
MX2021012392A (es) 2021-11-12
WO2020210684A1 (en) 2020-10-15
IL287120A (en) 2021-12-01
TW202104213A (zh) 2021-02-01
MA55624A (fr) 2022-02-16
US20220220094A1 (en) 2022-07-14
CN113939294A (zh) 2022-01-14
JP2022526015A (ja) 2022-05-20
ZA202107499B (en) 2022-06-29
AU2020272045A1 (en) 2021-10-28
EA202192530A1 (ru) 2022-03-15
AR118641A1 (es) 2021-10-20
KR20210151887A (ko) 2021-12-14

Similar Documents

Publication Publication Date Title
MX2022003984A (es) Compuestos heterociclicos antivirales.
PH12018502026A1 (en) Substituted indole compound derivatives as dengue viral replication inhibitors
NZ739226A (en) Benzodiazepine derivatives as rsv inhibitors
JOP20180113A1 (ar) مركبات ,تركيبات وطرق
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MX2018010983A (es) Derivado de 3-desoxi y composiciones farmaceuticas del mismo.
MY195194A (en) Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
BR112021011325A2 (pt) Derivados de rapamicina
BR112022009209A2 (pt) Derivado de amida e método de preparação e uso do mesmo na medicina
CO2021010493A2 (es) Compuestos de halo-alilamina y uso de los mismos
BR112021020027A2 (pt) Compostos, composições e métodos
EA202192845A1 (ru) Новые композиции, содержащие мелфлуфен
BR112020008258B8 (pt) Compostos de biarila substituída ou seus sais farmaceuticamente aceitáveis, sua composição e seu uso como inibidores de indoleamina 2,3-dioxigenase (ido)
BR112023002617A2 (pt) Compostos, composições e métodos
UY38614A (es) Derivados de benzodiazepinas como inhibidores del rsv
MX2023013683A (es) Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).
BR112023002077A2 (pt) Composto e seu uso, composição e formulação farmacêutica
UY39642A (es) Compuestos heterocíclicos antivirales
BR112022017779A2 (pt) Imunomodulação de azaletos de o-het-arila
BR112022014933A2 (pt) Compostos e composições para uso no tratamento de distúrbios de pele
BR112022007974A2 (pt) Inibidores de ssao e uso dos mesmos